Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles
Open Access
- 1 April 2016
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 24 (4) , 759-769
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute
This publication has 38 references indexed in Scilit:
- Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung CancerMolecular Therapy Nucleic Acids, 2013
- EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic MutationInternational Journal of Medical Sciences, 2013
- Macrophages in Tumor Microenvironments and the Progression of TumorsJournal of Immunology Research, 2012
- MicroRNA-125b Potentiates Macrophage ActivationThe Journal of Immunology, 2011
- Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseNature Protocols, 2009
- MicroRNA-125b is a novel negative regulator of p53Genes & Development, 2009
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase InhibitorsPLOS ONE, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004